|Title:||Updated results of a first-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies|
|Session:||Lung Cancer Localized /Metastatic|
|Date & Time:||Saturday, September 28, 11:15 a.m. (CEST)|
|Presenter:||D. Ross Camidge, M.D., Ph.D. (Colorado Cancer Center, Aurora, Colorado)|
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that updated data from its Phase 1/2 trial of AP26113, an investigational inhibitor of anaplastic lymphoma kinase (ALK), epidermal growth factor receptor (EGFR) and c-ros oncogene 1 (ROS1), will be presented at the European Cancer Congress (the 38 th ESMO, 32 nd ESTRO, 17 th ECCO) being held in Amsterdam, September 27 to October 1, 2013. Updated results from the ongoing Phase 1/2 trial will be featured in an oral presentation on Saturday, September 28, 2013. The schedule and meeting location for the session, together with the abstract information, are listed below: Oral Presentation at ECC 2013
About ARIAD ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts and Lausanne, Switzerland, is an integrated global oncology company focused on transforming the lives of cancer patients with breakthrough medicines. ARIAD is working on new medicines to advance the treatment of various forms of chronic and acute leukemia, lung cancer and other difficult-to-treat cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines. For additional information, visit http://www.ariad.com or follow ARIAD on Twitter ( @ARIADPharm).